76 related articles for article (PubMed ID: 11891671)
1. Clinical pharmacokinetic studies with INN 00835 (nemifitide), a novel pentapeptide antidepressant.
Feighner JP; Nicolau G; Abajian H; Marricco NC; Morrison J; Sverdlov L; Hlavka J; Tonelli G; Di Spirito C; Faria G
Biopharm Drug Dispos; 2002 Jan; 23(1):33-9. PubMed ID: 11891671
[TBL] [Abstract][Full Text] [Related]
2. Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers.
Nicolau G; Feighner JP; Stout R; Hlavka J; Gutierrez M; Ciric S; Freed J
Biopharm Drug Dispos; 2005 Dec; 26(9):379-85. PubMed ID: 16130176
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.
Liu MY; Meng SN; Wu HZ; Wang S; Wei MJ
Clin Ther; 2008 Apr; 30(4):641-53. PubMed ID: 18498913
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression.
Feighner JP; Ehrensing RH; Kastin AJ; Leonard BE; Sverdlov L; Nicolau G; Patel A; Hlavka J; Abajian H; Noble JF
J Affect Disord; 2000 Dec; 61(1-2):119-26. PubMed ID: 11099750
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet.
Schulz HU; Schürer M; Bässler D; Weiser D
Arzneimittelforschung; 2005; 55(1):15-22. PubMed ID: 15727160
[TBL] [Abstract][Full Text] [Related]
9. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder.
Montgomery SA; Feighner JP; Sverdlov L; Shrivastava RK; Cunningham LA; Kiev A; Hlavka J; Tonelli G
Int J Neuropsychopharmacol; 2006 Oct; 9(5):517-28. PubMed ID: 16259645
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression.
Overstreet DH; Hlavka J; Feighner JP; Nicolau G; Freed JS
Psychopharmacology (Berl); 2004 Sep; 175(3):303-9. PubMed ID: 14985919
[TBL] [Abstract][Full Text] [Related]
15. The effect of treatment with a new antidepressant, INN 00835, on platelet serotonin uptake in depressed patients.
Kelly JP; Nicolau G; Redmond A; Leonard BE; Noble J; Sverdlov L; Molinar R; Kastin AJ; Ehrensing RH; Feighner JP
J Affect Disord; 1999 Oct; 55(2-3):231-5. PubMed ID: 10628893
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment.
Feighner JP; Sverdlov L; Nicolau G; Abajian HB; Hlavka J; Freed JS; Tonelli G
Int J Neuropsychopharmacol; 2003 Sep; 6(3):207-13. PubMed ID: 12974986
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
19. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study.
Jiang J; Tian L; Huang Y; Li Y; Xu L
Clin Ther; 2008 Jul; 30(7):1290-9. PubMed ID: 18691988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
